Finally, a phase I clinical trial using autologous T cells expressing CD19-specific CAR (CD19-KIRS2/Dap12-BB) in adult relapsed/refractory (r/r) B-ALL patients with lymphodepleting chemotherapy was conducted to evaluate the anti-tumor activity and safety of CD19-KIRS2/Dap12-BB CAR-T cells compared with second-generation CAR-T cells targeting CD19. Here, CD19 is linked to neoplasm.